Market Spotlight: Acute Decompensated Heart Failure (ADHF)
Market Spotlight: Acute Decompensated Heart Failure (ADHF)
$1,318.00
This Market Spotlight report covers the Acute Decompensated Heart Failure (ADHF) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, probability of success, epidemiology information, licensing and asset acquisition deals, and drug-specific revenues.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Acute Decompensated Heart Failure (ADHF) market, comprising key marketed and pipeline drugs, upcoming events, clinical trials, probability of success, and epidemiology information.
Key Takeaways
- Approved drugs in the ADHF – preserved ejection fraction (acute HFpEF) space target natriuretic peptide receptors. These drugs are administered via the intravenous route.
- Approved drugs in the ADHF – reduced ejection fraction (acute HFrEF) space target natriuretic peptide receptors, phosphodiesterase 3, potassium channels, and troponin-C. All of the approved therapies are administered via the intravenous route, with two drugs also being available in an oral formulation.
- The majority of industry-sponsored drugs in active clinical development for acute HFrEF are in Phase II. Therapies in development for acute HFrEF target guanylate cyclase, ryanodine receptor, sarcoplasmic reticulum Ca2+-ATPase, troponin, beta-3 adrenergic receptor, relaxin family peptide receptors 1–4, and natriuretic peptide receptors. These therapies are administered via the intravenous and oral routes.
- High-impact upcoming events for drugs in the acute HFrEF space comprise topline Phase II trial results for istaroxime and topline Phase IIa trial results for APD418.
- The overall likelihood of approval of a Phase I acute HFrEF asset is 1.5%, and the average probability a drug advances from Phase III is 28.6%. Drugs, on average, take 13.6 years from Phase I to approval, compared to 10.2 years in the overall cardiovascular space.
- The distribution of clinical trials across Phase I–IV indicates that the majority of trials for ADHF have been in the late phases of development, with 58% of trials in Phase III–IV, and 42% in Phase I–II.
- Clinical trial activity in the ADHF space is dominated by completed trials. Johnson & Johnson has the highest number of completed clinical trials for ADHF, with 17 trials.
- Johnson & Johnson leads industry sponsors with the highest overall number of clinical trials for ADHF, followed by Novartis.
CONTENTS
5 OVERVIEW
6 KEY TAKEAWAYS
7 DISEASE BACKGROUND
7 Definition
7 Symptoms
7 Patient subtypes
7 Risk factors
7 Diagnosis
9 TREATMENT
9 Diuretics
9 Vasodilator therapy
10 Ultrafiltration (UF)
10 Inotropes
10 Natriuretic peptides
10 Vasopressors/Beta blockers/ACE inhibitors
11 Circulatory assist devices
11 Other therapies
12 EPIDEMIOLOGY
12 ADHF incidence
13 MARKETED DRUGS
13 Acute HFpEF
15 Acute HFrEF
17 PIPELINE DRUGS
17 Acute HFrEF
21 KEY UPCOMING EVENTS
21 Acute HFrEF
22 PROBABILITY OF SUCCESS
23 LICENSING AND ASSET ACQUISITION DEALS
23 Abiomed Buys Precardia
24 CLINICAL TRIAL LANDSCAPE
25 Sponsors by status
26 Sponsors by phase
27 Recent events
28 BIBLIOGRAPHY
29 APPENDIX
LIST OF FIGURES
17 Figure 1: Overview of pipeline drugs for acute HFrEF in the US
17 Figure 2: Pipeline drugs for acute HFrEF by, company
18 Figure 3: Pipeline drugs for acute HFrEF by, drug type
18 Figure 4: Pipeline drugs for acute HFrEF by, classification
21 Figure 5: Key upcoming events in acute HFrEF
22 Figure 6: Probability of success in the ADHF pipeline
24 Figure 7: Clinical trials in ADHF
24 Figure 8: Top 10 drugs for clinical trials in ADHF
25 Figure 9: Top 10 companies for clinical trials in ADHF
26 Figure 10: ADHF trials status
27 Figure 11: ADHF trials sponsors, by phase
LIST OF TABLES
14 Table 1: Marketed drugs for acute HFpEF
16 Table 2: Marketed drugs for acute HFrEF
19 Table 3: Pipeline drugs for acute HFrEF in the US
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Market Spotlight: Hidradenitis Suppurativa 
Sign up to the